Related by context. All words. (Click for frequent words.) 75 safety tolerability pharmacokinetic 73 pharmacodynamic PD 73 pharmacokinetics PK 72 pharmacodynamic profile 72 pharmacokinetic parameters 71 riociguat 71 plasma pharmacokinetics 71 pharmacodynamics PD 70 pharmacodynamic markers 70 pharmacokinetic characteristics 70 pharmacokinetic PK 70 dose proportionality 70 pharmacodynamic 70 pharmacodynamic parameters 69 OMP #M# 69 tolerability pharmacokinetics 69 STRIDE PD 69 pharmacodynamic properties 69 preclinically 69 pharmacokinetic PK profile 69 enzastaurin 69 viral kinetics 68 viral kinetic 68 cannabinor 68 Pharmacokinetic 68 safety tolerability pharmacokinetics 68 multicenter Phase II 68 MGd 68 antiviral efficacy 68 pertuzumab 68 teriflunomide 68 Azedra 68 antiangiogenic therapy 68 GAMMAGARD 68 urocortin 2 68 vidofludimus 68 PSMA ADC 68 MAGE A3 ASCI 68 intermittent dosing 68 antiresorptive 68 biodistribution 68 antitumor effect 68 oral deforolimus 68 mertansine 68 Maximum Tolerated Dose MTD 67 ascending dose 67 pharmacokinetics pharmacodynamics 67 ENMD # 67 maximally tolerated dose 67 galiximab 67 oral prodrug 67 HER2 expression 67 favorable pharmacokinetic profile 67 ELACYT 67 alvespimycin 67 pharmacokinetic profile 67 HGS ETR2 67 serum phosphorous 67 relapsed MM 67 mapatumumab 67 analgesic efficacy 67 Akt activation 67 ORMD 67 hematological parameters 67 cardiac repolarization 67 AEG# 67 CLORETAZINE TM VNP#M 67 ZOLINZA 67 pharmacokinetic interactions 67 avosentan 67 antiangiogenic 67 optimal dosing 67 nab paclitaxel 67 PXD# 67 immunological responses 67 CTAP# Capsules 67 Trofex 67 varespladib 66 XmAb# 66 selective modulator 66 budesonide foam 66 preclinical efficacy 66 Archexin 66 fosbretabulin 66 vorinostat 66 parathyroid hormone PTH 66 R#/MEM # 66 CIMZIA TM certolizumab pegol 66 pharmacokinetics 66 Blinatumomab 66 interleukin IL -# 66 endothelin antagonists 66 florbetaben 66 pharmacokinetic studies 66 phase Ib 66 Phase #b/#a trial 66 cardioprotective effects 66 Phase 1b trial 66 safety tolerability pharmacodynamics 66 Pharmacokinetic PK 66 Pharmacokinetic studies 66 cediranib 66 busulfan 66 TRV# [001] 66 pharmacodynamics 66 HGS ETR1 66 ritonavir boosted 66 trial evaluating PRX# 66 Phase Ib clinical 66 dose escalation phase 66 TACI Ig 66 Bezielle 66 urate lowering 66 GFT# 66 aplindore 66 CBLC# 66 APTIVUS r 66 serum biomarkers 66 Zemplar Capsules 66 HuMax EGFr 66 CR# vcMMAE 66 indibulin 66 CCX# 65 JAK inhibitor 65 Tyrima 65 inecalcitol 65 elotuzumab 65 vitro cytotoxicity 65 reactogenicity 65 Capesaris 65 Phase Ib study 65 oral rivaroxaban 65 randomized multicenter trial 65 GLYX 65 clevidipine 65 pharmacodynamic endpoints 65 CIMZIA ™ 65 neratinib 65 nucleotide analog 65 pharmacokinetic 65 corticosteroid dexamethasone 65 Traficet EN 65 prospective multicentre 65 CXB# 65 Pharmacokinetic parameters 65 pharmacodynamic profiles 65 Androxal TM 65 ALB # 65 fumagillin nanoparticles 65 antiproliferative effects 65 systemically administered 65 hemodynamic variables 65 eTag assays 65 Ceplene/IL-2 65 PRTX 65 anticancer activity 65 confirmatory clinical 65 RLY# 65 orally dosed 65 ganetespib 65 #I TM# 65 novel VDA molecule 65 Phase IIIb clinical 65 Tumor Response 65 receptor inhibitor 65 antitumour activity 65 APTIVUS 65 anti leukemic 65 IMC A# 65 tanespimycin 65 nonclinical studies 65 imetelstat 65 subcutaneous PRO 65 forodesine 65 VA# [002] 65 limiting toxicity DLT 65 flavopiridol 65 Enzastaurin 65 HCV SPRINT 65 Aclidinium 65 Imprime PGG 65 PEG SN# 65 NOX E# 65 metaglidasen 65 potent suppressor 65 Panzem R NCD 65 Poly ICLC 65 TRO# 65 Elocalcitol 65 GOUT 65 Ophena TM 65 Symadex 65 pharmacokinetic equivalence 65 pomalidomide 64 MEND CABG II 64 radiolabeled TM# 64 CIMZIA TM 64 velafermin 64 ADAGIO study 64 phase IIa clinical 64 glycosylated hemoglobin HbA1c 64 TOLAMBA 64 vitro experiments 64 uricase 64 Degarelix 64 mg/m2 cohort 64 KRAS status 64 Chemophase 64 bronchodilatory 64 Teriflunomide 64 Ocrelizumab 64 Novolimus 64 5alpha reductase 64 motesanib 64 PRT# 64 INCB# [001] 64 Tasigna prolongs 64 Phase Ib II 64 Darusentan 64 efficacy tolerability 64 hyperphenylalaninemia HPA due 64 plasma kallikrein inhibitor 64 Triolex 64 F FDG PET 64 CA4P 64 tolerated dose MTD 64 factor Xa 64 elacytarabine 64 Phase IIb III 64 NATRECOR ® 64 pharmacokinetic PK study 64 azilsartan medoxomil 64 PSN# [002] 64 Phase 1a clinical 64 RE LY ® 64 antitumor activity 64 DermaVir Patch 64 radiolabeled 64 CINQUIL 64 PROCHYMAL 64 KRN# 64 Non inferiority 64 Trandolapril 64 AMD# [003] 64 placebo controlled dose escalation 64 GAP #B# 64 pyridostigmine 64 NP2 Enkephalin 64 BMS# 64 REMINYL ® 64 APOPTONE 64 thorough QT 64 ISIS # 64 mTOR inhibitors 64 Apoptone 64 Phase Ia 64 antitumor effects 64 BAY #-# 64 Telatinib 64 bezafibrate 64 epoetin alpha 64 masitinib 64 TMC# [002] 64 antifibrotic 64 CG# [003] 64 ibandronate 64 Pharmacodynamic 64 CoFactor 64 iloprost 64 PS# [001] 64 AKT inhibitor 64 rFIXFc 64 histone deacetylase inhibitor 64 MP4OX 64 EDEMA3 trial 64 oral FTY# 64 tumorigenicity 64 crizotinib PF # 64 davunetide intranasal AL 64 Phase 2b study 64 cilengitide 64 DAVANAT 64 prucalopride 64 pharmacokinetic pharmacodynamic 64 Phase 2a trial 64 Omacetaxine mepesuccinate 64 serum cortisol 64 LY# [002] 64 nonrandomized 64 NGX# 64 phase IIb trial 64 alkylating agent 64 GSK# [001] 64 placebo controlled clinical 64 Phase #b/#a 64 lactate dehydrogenase LDH 64 PRIMO CABG 64 BNC# 64 metabolic parameters 64 ASTEROID 64 Phase 1a 64 neurologic progression 64 renal toxicity 64 dose escalation clinical 64 LAB CGRP 63 RG# ITMN 63 mecamylamine 63 Aflibercept 63 Ostarine 63 K ras mutations 63 5 HT2C receptor 63 omega interferon 63 Natalizumab 63 trastuzumab Herceptin ® 63 antitumor efficacy 63 radiation dosimetry 63 CYT# potent vascular disrupting 63 Subgroup analysis 63 NU# [001] 63 ZD# [001] 63 desvenlafaxine succinate 63 IAP inhibitor 63 CYP#C# genotype 63 RSD# oral 63 paricalcitol 63 trodusquemine 63 Phase 1b 63 lomitapide 63 ThGRF 63 edifoligide 63 Telintra 63 dosage regimens 63 Pralatrexate 63 HCV RESPOND 2 63 MEND CABG 63 orally bioavailable 63 brivaracetam 63 Triapine R 63 plasma renin activity 63 TLK# 63 Phase IIB 63 TRIOLEX 63 Aliskiren 63 GLPG# 63 intravenous dosing 63 pharmacokinetic profiles 63 alicaforsen enema 63 MET amplification 63 Cloretazine 63 ruxolitinib 63 Pertuzumab 63 PRIMO CABG2 63 pharmacodynamic mechanism 63 tipifarnib 63 bicifadine 63 antidepressant efficacy 63 Vascugel 63 HMG CoA reductase inhibitors 63 retaspimycin 63 mGluR2 NAM 63 irbesartan 63 anti resorptive 63 ON #.Na 63 Virulizin ® 63 Sym# 63 EGFR HER 63 PROactive study 63 eniluracil 63 fulvestrant 63 DLTs 63 Genz # 63 mg/m2 dose 63 YONDELIS 63 immune modulatory 63 SCH # 63 gamma secretase inhibitor 63 HQK 63 phase IIb study 63 Pemetrexed 63 dose proportional pharmacokinetics 63 huN# DM1 63 Phase Ib clinical trials 63 Safinamide 63 serum urate levels 63 eprotirome 63 Dose escalation 63 Amphinex ® 63 Phase IIa trial 63 elastase 63 RezularTM 63 OXi# 63 blinded randomized placebo controlled 63 investigational humanized monoclonal antibody 63 erythropoietic 63 CORT # 63 HIF PH inhibitors 63 ADME properties 63 plasma kallikrein 63 FOLPI 63 Secondary endpoints 63 talabostat 63 urinary N telopeptide 63 ABSORB trial 63 corrected QT interval 63 bortezomib Velcade 63 sitaxsentan 63 bovine thrombin 63 Exelixis compounds 63 secretory phospholipase A2 sPLA2 63 demonstrated antitumor activity 63 efficacy endpoint 63 GLP toxicology studies 63 CA9 SCAN 63 RE LY trial 63 tumor hypoxia 63 obatoclax 63 experimentally induced 63 visilizumab 63 ACTEMRA TM 63 serum lipid 63 prospectively stratified 63 Primary endpoints 63 triphendiol 63 antiarrhythmic 63 evaluating tivozanib 63 peripheral blood mononuclear 63 inflammatory biomarkers 63 IRX 2 63 axitinib 63 nalbuphine ER 63 Lixivaptan 63 Aurora Kinase 63 Deforolimus 63 MVA MUC1 IL2 63 ISF# 63 tolerability profiles 63 glomerular filtration 63 EOquin TM 63 randomized multicenter Phase III 63 recurrent glioblastoma multiforme 63 CYP#A# CYP#D# 63 intravesical 63 metabolite concentrations 63 phase IIb clinical 63 INSPIRE Trial Phase III 63 GRNCM1 63 trastuzumab emtansine T DM1 63 Secondary efficacy endpoints 63 rifalazil 63 GSK# [002] 63 preclinical pharmacokinetic 63 dosing cohort 63 Pimavanserin 63 Zemiva 63 administered subcutaneously 63 #beta estradiol 63 Plasma concentrations 62 serum leptin 62 IMA# 62 potentiation 62 ATL# [001] 62 Spiegelmer ® 62 ToGA 62 statistically significant efficacy 62 Seliciclib 62 pegylated liposomal doxorubicin 62 BoNTA 62 LEP ETU 62 FDG uptake 62 PEG PAL 62 anti amnesic 62 Cardiotoxicity 62 cytoprotective 62 blinded randomized 62 Posiphen 62 ascending doses 62 GMX# 62 multicenter randomized placebo controlled 62 midstage clinical 62 multicenter randomized controlled 62 mixed hyperlipidemia 62 clinically meaningful improvement 62 MetAP2 62 LSI #P 62 Antiangiogenic 62 longitudinal observational study 62 Golimumab 62 sub maximal 62 tasimelteon 62 generation antisense inhibitor 62 farletuzumab 62 Sapacitabine 62 antiandrogens 62 tissue oxygenation 62 Linagliptin 62 relapsed MCL 62 dose cohort 62 Darinaparsin 62 PITX2 methylation 62 alpha#beta# integrin 62 CRLX# 62 RECIST Response Evaluation Criteria 62 CK # administered 62 intra articular injection 62 Solorel TM 62 HIV HCV coinfected 62 Lp PLA 2 62 Phase 1b clinical trials 62 QTc prolongation 62 antiangiogenesis 62 randomized blinded 62 multicentre randomized 62 EDEMA3 62 Randomized Double blind 62 Ataluren 62 AZILECT R 62 Anacetrapib 62 murine models 62 IFN beta 62 MEK inhibitor 62 mTOR inhibition 62 flurpiridaz F 62 tolerability 62 eosinophil count 62 Dasatinib 62 BFPET 62 active comparator 62 pramlintide metreleptin combination 62 delafloxacin 62 OHR/AVR# 62 P selectin 62 milatuzumab 62 prospectively defined 62 Pharmacokinetics PK 62 cardiac toxicity 62 immune modulating 62 S/GSK# 62 IFN α 62 Insulin PH# 62 treatment naive genotype 62 TNFalpha 62 Corus CAD 62 bleomycin 62 liposomal formulation 62 DCCR 62 solithromycin 62 dexpramipexole 62 anti fibrotic 62 CDK inhibitor 62 Maximum Tolerated Dose 62 EndoTAG TM -1 62 TPI ASM8 62 natriuretic peptide 62 DEB# 62 synthetic retinoid 62 ataluren 62 dose escalation trial 62 MGN# 62 Microplasmin 62 teduglutide 62 GRN# 62 dose escalation Phase 62 thromboxane A2 62 TH# [003] 62 ACAPODENE 62 AOD# [002] 62 ATACAND 62 CD# expressing 62 Oral NKTR 62 Kinoid 62 effector function 62 HepG2 cells 62 optimal dosing regimens 62 prostate cancer PCa 62 factor Xa inhibitor 62 coadministration 62 liposomal doxorubicin 62 EchoCRT 62 NAbs 62 antiangiogenic agent 62 goserelin 62 pain palliation 62 HGS# 62 inhibit platelet function 62 LB# [003] 62 endothelial activation 62 p# biomarker 62 inhibitory effects 62 verteporfin 62 kinase inhibition 62 PI3K/mTOR 62 SYMMETRY trial 62 dose limiting toxicities 62 OBPM 62 glycemia 62 LT NS# 62 Antitumor Activity 62 pleiotropic effects 62 tarenflurbil 62 Aplidin 62 morphometric vertebral fractures 62 Anturol TM 62 CRMD# 62 dacetuzumab 62 CD# upregulation 62 favorable pharmacokinetic 62 genotypic resistance 62 microvessel density 62 Ozarelix 62 PRADAXA 62 hepatotoxic 62 Immunomodulatory 62 FDG-PET/CT 62 cariprazine 62 rtPA 62 MoxDuo TM IR 62 HCV replicon 62 Amplimexon 62 XL# inhibits 62 selective agonist 62 denileukin diftitox 62 Carfilzomib 62 subcutaneously administered 62 Darapladib 62 trastuzumab DM1 62 cobiprostone 62 randomized Phase 2b 62 IMPACT DCM 62 estramustine 62 Phase Ib 62 potent antiproliferative 62 deforolimus 62 CARE HF 62 phase IIa 62 hydroxy vitamin D 62 EndoTAGTM 1 62 Zybrestat 62 ZACTIMA 62 dose dependently 62 intracoronary 62 EGFR TKI 62 oral ridaforolimus 62 antiangiogenic agents 62 lucinactant 62 zoledronate 62 erlotinib Tarceva ® 62 Vidaza azacitidine 62 Lp PLA2 62 R baclofen 62 Granulocyte Colony Stimulating Factor 62 intact parathyroid hormone 62 Phase IIb clinical trials 62 brachial artery flow 62 C1 INH 62 telomerase inhibition 62 insulin sensitizing 62 enzyme inhibitor 62 rNAPc2 62 hMG 62 therapeutically relevant 62 apremilast 62 AVADO 62 efficacy 62 Rigel R# 62 Genasense ® oblimersen 62 EVIZON 62 Tiotropium 62 INS# [001] 62 PRX# 62 microdose 61 Zoraxel 61 heparanase 61 HIF 1a 61 Dapagliflozin 61 CTCE 61 selective androgen receptor modulator 61 incretin 61 Randomized Phase 61 HuMax CD# 61 topoisomerase II inhibitor 61 VP# [004] 61 pegylated IFN 61 safety tolerability 61 Arikace 61 antiapoptotic 61 pitavastatin 61 Onconase 61 dose escalation 61 acadesine 61 TIMP 1 61 anti CD3 61 Fulvestrant 61 BrachySil TM 61 DFMO 61 serum antibody 61 Afatinib 61 topically administered 61 REG1 61 lintuzumab 61 AST ALT 61 AZILECT ® 61 alagebrium 61 DU #b 61 Initiate Phase 61 latrepirdine 61 ERK1 2 61 tolevamer 61 #mg BID [003] 61 rALLy clinical trial 61 5 HT2A 61 multicenter Phase 61 antiangiogenic activity 61 hepatic fibrosis 61 PhG alpha 1 61 chronic thromboembolic pulmonary 61 Phase #/#a 61 Xelox 61 pancreatic polypeptide 61 Squalamine 61 mGluR5 NAM 61 antibody MAb 61 subgroup analyzes 61 tipranavir r 61 Proellex TM 61 randomized multicenter 61 thymalfasin 61 integrin receptor 61 MYDICAR ® 61 rhIGFBP 3 61 Denufosol 61 ONTARGET 61 multiple ascending dose 61 huC# DM4 61 plasma triglycerides 61 prospective multicenter study 61 prospective randomized multicenter 61 Preclinical Study 61 Lisofylline LSF 61 vivo potency 61 Hemospan R 61 favorable tolerability 61 mycophenolate mofetil 61 Elagolix 61 plasma lipid 61 Kahalalide F 61 metreleptin 61 LY# [003] 61 CardioPET 61 intima media thickness 61 Phase IIa trials 61 CANCIDAS 61 Mipomersen 61 prospective multicenter randomized 61 epigenetic therapies 61 intravenous cyclophosphamide 61 somatostatin analog 61 PROMACTA 61 sargramostim 61 VAPRISOL 61 achieved statistical significance 61 CRESTOR #mg 61 Phase #b/#a clinical 61 MVax 61 angiographic outcomes 61 SABCS 61 angiogenesis inhibitor 61 sustained virological response 61 im peramivir 61 regorafenib 61 NPM1 mutation 61 potent anti angiogenic 61 FFNS 61 HuLuc# 61 serum concentrations 61 CTA# 61 doxorubicin cyclophosphamide 61 maximal tolerated 61 hyperinsulinemic euglycemic clamp 61 Naive Patients 61 Anavex #-# 61 lumiliximab 61 Vaxfectin TM 61 Annamycin 61 CCR5 mAb 61 IL 1ß 61 MAGE A3 61 Glypromate 61 iniparib 61 Hsp# Inhibitor 61 tumor histology 61 Diamyd r vaccine 61 hemodilution 61 systemic hypotension 61 torsemide ER 61 Hematologic toxicity 61 samalizumab 61 thalidomide Thalomid 61 #F FDG PET 61 BAL# [002] 61 pan HDAC inhibitor 61 cytotoxic effects 61 left ventricular diastolic 61 GRN#L 61 ApoA1 61 gonadotrophin releasing hormone GnRH 61 Immunohistochemical analysis 61 DXL# 61 PDE# inhibitors 61 Cardiorespiratory fitness 61 glucagon receptor 61 neuroregenerative 61 HCD# [002] 61 CYP#D# genotype 61 interferon γ 61 secondary efficacy endpoint 61 dose escalation study 61 clomipramine 61 Acute Ischemic Stroke 61 Arranon 61 TriRima 61 TG# [003] 61 sulodexide 61 orally administered inhibitor 61 OMS# 61 CIPN 61 investigational protease inhibitor 61 Hedgehog inhibitor 61 gemcitabine Gemzar ® 61 platelet inhibitor 61 MoxDuo ® IR 61 aminotransferases 61 virus HCV protease inhibitor 61 AAG geldanamycin analog 61 androgen suppression 61 ASSERT trial 61 glycated hemoglobin levels 61 randomized Phase IIb 61 tecarfarin 61 Aptivus ® 61 rindopepimut 61 olaparib 61 glatiramer acetate 61 HORIZONS AMI trial 61 hemoglobin A1c HbA1c 61 aspirin clopidogrel 61 Multiple Ascending Dose 61 BRAF inhibitors 61 Tasimelteon 61 PSADT 61 APPRAISE 61 imatinib therapy 61 Outpatient Setting 61 novel chimeric natriuretic 61 ESBA# 61 LEXIVA r 61 SRT# [003] 61 alkaline phosphatase ALP 61 ONCONASE R 61 HDL Mimetic Peptide 61 superficial bladder cancer 61 PKC# 61 PEGPH# 61 Navelbine 61 ERalpha 61 cisplatin resistant 61 torezolid phosphate 61 initiate Phase 2b 61 Quinamed 61 PI3K/Akt pathway inhibitor 61 lanthanum carbonate 61 ZYBRESTAT fosbretabulin 61 ImmunoVEX HSV2 61 FGFs 61 eltrombopag 61 BRIM2 61 cMET 61 intravenously administered 61 fibrotic disease 61 RhuDex R 61 alpha 2A 61 intensive lipid lowering 61 glucose lowering 61 neuroprotective properties 61 radiosensitivity 61 DaTscan 61 lenalidomide dexamethasone 61 deCODE AF TM 61 P#Y# [002] 61 VerifyNow 61 oral methylnaltrexone 61 multicenter trials 61 Methylnaltrexone 61 d dimer 61 fluvastatin 61 surrogate endpoint 61 intraventricular 61 Xanafide 61 CCR9 antagonist 61 Vidofludimus 61 CYT# QbG# 61 antitumoral 61 PRX # 61 muscarinic 61 Secondary endpoints include 61 metabolomic profiling 61 transgene expression 61 Exherin TM 61 Bosutinib 61 TNF alpha inhibitor 61 standard chemotherapy regimen 61 vascular disrupting agent 61 oral picoplatin 61 JAK inhibitors 61 GLP1 agonist 61 immunohistochemical 61 subanalysis 61 HDL Selective Delipidation 61 salmeterol fluticasone 61 rosuvastatin #mg 61 icatibant 61 Tolvaptan 61 LHRH agonists 61 anti coagulant therapy 61 clinically meaningful reductions 61 Omacetaxine 61 #mg dose [001] 61 CFTR function 61 Phase IIA 61 IFN g 61 placebo controlled randomized 61 ImmuKnow 61 demonstrated clinically meaningful 61 decitabine 61 antimuscarinic 61 multicenter Phase III 61 Neuropsychiatric Inventory NPI 61 gefitinib Iressa 61 isoproterenol 61 #ME# 61 primidone 61 refractory prostate cancer 61 BRAF inhibitor 61 prognostic significance 61 steroid dexamethasone 61 assessing T DM1 61 tolvaptan 60 microsomal 60 AEGR 60 6R BH4 60 Plasmin 60 Cannabinor 60 ispinesib administered 60 tumor subtypes 60 pegnivacogin 60 Antiviral Activity 60 Alequel 60 enoximone 60 amifostine 60 RG# [001] 60 otelixizumab 60 mesothelin 60 VKORC1 60 double blinded placebo 60 INVEGA ® 60 Metastatic Melanoma 60 PEGylated anti 60 beta 1a 60 immunohistochemical analysis 60 ILLUMINATE 60 Cimzia TM 60 compound AEZS 60 GW# [003] 60 rhITF 60 Tanespimycin 60 INS# [002] 60 MYDICAR 60 liposomal amphotericin B 60 oral talactoferrin 60 candesartan cilexetil 60 ZFP TF 60 clinical pharmacology studies 60 registrational trial 60 aminotransferase levels 60 posaconazole 60 recurrent glioma 60 opioid naïve 60 protein excretion 60 mg kg BID 60 INT# [002] 60 PRESEPT 60 registrational 60 sipuleucel T 60 PYY3 60 rHuEPO 60 GRAVITAS trial 60 SAR# [002] 60 midstage trials 60 MIRCERA 60 IIa trials